LMLawton D. Murdolo

Lawton D. Murdolo

*This is an algorithmically generated author record based on publicly available information.

Lawton D. Murdolo has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Stephanie Gras

    GenomEast platform, IGBMC, 67404 Illkirch, France

    3 shared publications
  • Archana Panikkar

    QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory, Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, Australia

    2 shared publications
  • Christopher Szeto

    Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia

    2 shared publications
  • Corey Smith

    QIMR Berghofer Medical Research Institute

    2 shared publications
  • Demetra Chatzileontiadou

    Infection and Immunity Program La Trobe Institute for Molecular Science (LIMS) Bundoora VIC Australia

    2 shared publications
  • Jyothy Raju

    QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory, Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, Australia

    2 shared publications

Latest Publications

  • Open Access

    Assessing CD8 + T cell cross‐reactivity to influenza A, B and C virus‐derived peptides presented by HLA‐B*18:01

    by Lawton D Murdolo, Samuel Liwei Leong, Janesha C Maddumage, Lloyd D'ORsogna, Demetra Sm Chatzileontiadou, Emma J Grant, Stephanie Gras

    Objectives: Despite the availability of vaccines, influenza viruses still cause substantial morbidity and mortality. This highlights the need for improved vaccines and novel therapeutics. CD8 + T cells recognise conserved viral epitopes and can provide broad protection, making them attractive targets for next‐generation vaccine design. A key step in this process is to identify T cell epitopes across influenza viruses. Here, we characterised three homologous influenza Polymerase Basic 1 (PB1)‐derived peptides from influenza viruses (PB1‐A 310 , PB1‐B 310 and PB1‐C 312 , respectively) presented by the common, but understudied, HLA‐B*18:01 molecule. Methods: We used a thermal melt assay and X‐ray crystallography to assess the stability and structural features of each peptide. CD8 + T‐cell responses were evaluated using intracellular cytokine staining with HLA‐B*18:01 + samples. Results: The structures of HLA‐B*18:01 presenting each peptide were solved, including the first structure of HLA‐B*18:01 presenting a Gammainfluenzavirus (formerly influenza C virus) derived peptide. PB1‐C 312 exhibited a higher thermal stability and a different conformation compared to PB1‐A 310 and PB1‐B 310 . CD8 + T cell responses varied among samples, with PB1‐A 310 eliciting the strongest activation. Minimal T cell cross‐reactivity was observed and was mostly between PB1‐A 310 and PB1‐B 310 likely reflecting shared structural features. Conclusion: These findings further expand knowledge on peptide presentation by the common HLA‐B*18:01 molecule, and the limitations on CD8 + T cell cross‐recognition of this PB1‐derived epitope across influenza lineages. This highlights the importance of more research on cross‐lineage T cell cross‐reactivity that could inform the design of broadly protective T cell‐based vaccines and therapeutics.

  • Top Cited Papers
    Open Access

    A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection

    by Danillo G. Augusto, Lawton D. Murdolo, Demetra S. M. Chatzileontiadou, Joseph J. Sabatino, Tasneem Yusufali, Noah D. Peyser, Xochitl Butcher, Kerry Kizer, Karoline Guthrie, Victoria W. Murray, et al.

    Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2 remain asymptomatic1–4. Although most global efforts have focused on severe illness in COVID-19, examining asymptomatic infection provides a unique opportunity to consider early immunological features that promote rapid viral clearance. Here, postulating that variation in the human leukocyte antigen (HLA) loci may underly processes mediating asymptomatic infection, we enrolled 29,947 individuals, for whom high-resolution HLA genotyping data were available, in a smartphone-based study designed to track COVID-19 symptoms and outcomes. Our discovery cohort (n = 1,428) comprised unvaccinated individuals who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci with disease course and identified a strong association between HLA-B*15:01 and asymptomatic infection, observed in two independent cohorts. Suggesting that this genetic association is due to pre-existing T cell immunity, we show that T cells from pre-pandemic samples from individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF. The majority of the reactive T cells displayed a memory phenotype, were highly polyfunctional and were cross-reactive to a peptide derived from seasonal coronaviruses. The crystal structure of HLA-B*15:01–peptide complexes demonstrates that the peptides NQKLIANQF and NQKLIANAF (from OC43-CoV and HKU1-CoV) share a similar ability to be stabilized and presented by HLA-B*15:01. Finally, we show that the structural similarity of the peptides underpins T cell cross-reactivity of high-affinity public T cell receptors, providing the molecular basis for HLA-B*15:01-mediated pre-existing immunity.


  • Open Access

    Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3

    by Srividhya Swaminathan, Katie E. Lineburg, Archana Panikkar, Jyothy Raju, Lawton D. Murdolo, Christopher Szeto, Pauline Crooks, Laetitia Le Texier, Sweera Rehan, Michael J. Dewar-Oldis, et al.

    The emergence of the SARS-CoV-2 Omicron variant has raised concerns of escape from vaccine-induced immunity. A number of studies have demonstrated a reduction in antibody-mediated neutralization of the Omicron variant in vaccinated individuals. Preliminary observations have suggested that T cells are less likely to be affected by changes in Omicron. However, the complexity of human leukocyte antigen genetics and its impact upon immunodominant T cell epitope selection suggests that the maintenance of T cell immunity may not be universal. In this study, we describe the impact that changes in Omicron BA.1, BA.2 and BA.3 have on recognition by spike-specific T cells. These T cells constitute the immunodominant CD8+ T cell response in HLA-A*29:02+ COVID-19 convalescent and vaccinated individuals; however, they fail to recognize the Omicron-encoded sequence. These observations demonstrate that in addition to evasion of antibody-mediated immunity, changes in Omicron variants can also lead to evasion of recognition by immunodominant T cell responses.


  • Open Access

    Ablation of CD8+ T-cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron

    by Corey Smith, Srividhya Swaminathan, Katie Lineburg, Archana Panikkar, Jyothy Raju, Lawton Murdolo, Christopher Szeto, Pauline Crooks, Laëtitia Le Texier, Sweera Rehan, et al.

    The emergence of the SARS-CoV-2 Omicron variant has raised concerns of escape from vaccine-induced immunity. A number of studies have demonstrated a reduction in antibody-mediated neutralization of the Omicron variant in vaccinated individuals. Preliminary observations have suggested that T cells are less likely to be affected by changes in Omicron. However, the complexity of human leukocyte antigen genetics and its impact upon immunodominant T-cell epitope selection suggests that the maintenance of T-cell immunity won’t be universal. In this study, we describe the impact that changes in Omicron have on recognition by spike-specific T cells. These T cells constitute the immunodominant CD8+ T-cell response in HLA-A*29:02+ COVID-19 convalescent and vaccinated individuals; however, they fail to recognize the Omicron-encoded sequence. We also failed to detect other immunodominant responses in vaccinated HLA-A*29:02+ individuals, suggesting that the Omicron variant may have an increased capacity to escape immune recognition in this population.